ZA200504109B - Escitalopram hydrobromide and a method for the preparation thereof - Google Patents

Escitalopram hydrobromide and a method for the preparation thereof Download PDF

Info

Publication number: ZA200504109B
Authority: ZA; South Africa
Prior art keywords: disorder; disorders; escitalopram; escitalopram hydrobromide; hydrobromide
Prior art date: 2002-12-23

Application number

ZA200504109A

Other languages

English (en)

Inventor

Lawrence Martel

Robert Dancer

Hans Petersen

Peter Ellegaard

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2005-05-20

Publication date

2006-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200504109(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-20 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2006-08-30 Publication of ZA200504109B publication Critical patent/ZA200504109B/en

Links

WIHMBLDNRMIGDW-BDQAORGHSA-N escitalopram hydrobromide Chemical compound Br.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WIHMBLDNRMIGDW-BDQAORGHSA-N 0.000 title claims description 14
238000000034 method Methods 0.000 title description 7
238000002360 preparation method Methods 0.000 title description 5
206010029333 Neurosis Diseases 0.000 claims description 5
208000015238 neurotic disease Diseases 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
206010041250 Social phobia Diseases 0.000 claims description 4
208000019906 panic disease Diseases 0.000 claims description 4
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 3
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
208000032841 Bulimia Diseases 0.000 claims description 2
206010006550 Bulimia nervosa Diseases 0.000 claims description 2
208000020401 Depressive disease Diseases 0.000 claims description 2
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 2
206010013654 Drug abuse Diseases 0.000 claims description 2
208000030814 Eating disease Diseases 0.000 claims description 2
208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
208000030990 Impulse-control disease Diseases 0.000 claims description 2
208000008589 Obesity Diseases 0.000 claims description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
206010033664 Panic attack Diseases 0.000 claims description 2
206010034912 Phobia Diseases 0.000 claims description 2
206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
208000026345 acute stress disease Diseases 0.000 claims description 2
208000022531 anorexia Diseases 0.000 claims description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
208000010877 cognitive disease Diseases 0.000 claims description 2
206010061428 decreased appetite Diseases 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
235000014632 disordered eating Nutrition 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
208000024732 dysthymic disease Diseases 0.000 claims description 2
208000029364 generalized anxiety disease Diseases 0.000 claims description 2
238000011221 initial treatment Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
235000020824 obesity Nutrition 0.000 claims description 2
208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
201000001716 specific phobia Diseases 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
208000008811 Agoraphobia Diseases 0.000 claims 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 29
229960004341 escitalopram Drugs 0.000 description 17
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 17
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 14
239000000243 solution Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 13
229960004592 isopropanol Drugs 0.000 description 11
150000003839 salts Chemical class 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 10
239000003921 oil Substances 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000007789 gas Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
229960001653 citalopram Drugs 0.000 description 5
239000012458 free base Substances 0.000 description 5
229910000042 hydrogen bromide Inorganic materials 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 4
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
238000001035 drying Methods 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
238000010533 azeotropic distillation Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
229940043265 methyl isobutyl ketone Drugs 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000011343 solid material Substances 0.000 description 2
YXCRMKYHFFMNPT-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1C2=CC=C(C#N)C=C2CO1 YXCRMKYHFFMNPT-UHFFFAOYSA-N 0.000 description 1
239000001358 L(+)-tartaric acid Substances 0.000 description 1
235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000001511 high performance liquid chromatography nuclear magnetic resonance spectroscopy Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000012265 solid product Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ZA200504109A 2002-12-23 2005-05-20 Escitalopram hydrobromide and a method for the preparation thereof ZA200504109B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200202005		2002-12-23

Publications (1)

Publication Number	Publication Date
ZA200504109B true ZA200504109B (en)	2006-08-30

Family

ID=32668635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200504109A ZA200504109B (en)	2002-12-23	2005-05-20	Escitalopram hydrobromide and a method for the preparation thereof

Country Status (33)

Country	Link
US (1)	US20040167209A1 (ru)
EP (1)	EP1578738B1 (ru)
JP (2)	JP4658613B2 (ru)
KR (1)	KR20050086933A (ru)
CN (1)	CN100349885C (ru)
AR (1)	AR042652A1 (ru)
AT (1)	ATE388947T1 (ru)
AU (1)	AU2003287919B2 (ru)
BR (1)	BR0317623A (ru)
CA (1)	CA2511142A1 (ru)
CY (1)	CY1107451T1 (ru)
DE (1)	DE60319739T2 (ru)
DK (1)	DK1578738T3 (ru)
EA (1)	EA013116B1 (ru)
EG (1)	EG24729A (ru)
ES (1)	ES2298595T3 (ru)
HK (1)	HK1087708A1 (ru)
IL (1)	IL169125A0 (ru)
IS (1)	IS2654B (ru)
ME (1)	MEP5808A (ru)
MX (1)	MXPA05005772A (ru)
MY (1)	MY135468A (ru)
NO (1)	NO20053595L (ru)
NZ (1)	NZ540281A (ru)
PE (1)	PE20040924A1 (ru)
PL (1)	PL378275A1 (ru)
PT (1)	PT1578738E (ru)
RS (1)	RS51092B (ru)
TW (1)	TW200501943A (ru)
UA (1)	UA80170C2 (ru)
UY (1)	UY28148A1 (ru)
WO (1)	WO2004056791A1 (ru)
ZA (1)	ZA200504109B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050137255A1 (en) *	2002-12-23	2005-06-23	H. Lundbeck A/S	Crystalline escitalopram hydrobromide and methods for preparing the same
MXPA05005772A (es) *	2002-12-23	2005-08-16	Lundbeck & Co As H	Bromhidrato de escitalopram y un metodo para su preparacion.
WO2005084643A1 (en) *	2004-03-05	2005-09-15	H. Lundbeck A/S	Crystalline composition containing escitalopram oxalate
TWI358407B (en)	2005-06-22	2012-02-21	Lundbeck & Co As H	Crystalline base of escitalopram and orodispersibl
US7834201B2 (en)	2005-06-22	2010-11-16	H. Lundbeck A/S	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EA200801081A1 (ru) *	2005-10-14	2008-10-30	Х. Лундбекк А/С	Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070112075A1 (en) *	2005-10-14	2007-05-17	Forest Laboratories, Inc.	Stable pharmaceutical formulations containing escitalopram and bupropion
TW200812993A (en) *	2006-05-02	2008-03-16	Lundbeck & Co As H	New uses of escitalopram
TWI399375B (zh) *	2006-07-11	2013-06-21	Mitsubishi Tanabe Pharma Corp	嗎啉化合物之鹽
WO2008059514A2 (en) *	2006-07-31	2008-05-22	Cadila Healthcare Limited	Process for preparing escitalopram
FR3006594A1 (fr) *	2013-06-11	2014-12-12	Sorin Crm Sas	Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) *	2017-06-05	2022-12-06	上海奥博生物医药股份有限公司	一种艾司西酞普兰双羟萘酸盐新的制备方法
JP7237269B2 (ja) *	2017-10-09	2023-03-13	４２８ファーマビーブイ．	エスシタロプラムの新しい塩および固体形態
US20240100012A1 (en)	2021-01-18	2024-03-28	Mark Hasleton	Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US34712A (en) *		1862-03-18		James h
GB1526331A (en) *	1976-01-14	1978-09-27	Kefalas As	Phthalanes
GB8419963D0 (en) *	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
WO2000023431A1 (en) *	1998-10-20	2000-04-27	H. Lundbeck A/S	Method for the preparation of citalopram
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
PT1298124E (pt) *	1999-10-25	2007-05-31	Lundbeck & Co As H	Método para a preparação de citalopram
US6977306B2 (en) *	2000-05-02	2005-12-20	Sumitomo Chemical Company, Limited	Citalopram hydrobromide crystal and method for crystallization thereof
JP2002020379A (ja) *	2000-05-02	2002-01-23	Sumika Fine Chemicals Co Ltd	シタロプラム臭化水素酸塩の結晶およびその結晶化方法
CA2353693C (en) *	2000-08-10	2003-07-22	H. Lundbeck A/S	Pharmaceutical composition containing citalopram
EP1339817B1 (de) *	2000-12-04	2007-06-13	Westfalia Separator AG	Verfahren zur herstellung von fettsaüreestern
CA2445843A1 (en) *	2001-05-01	2002-11-07	H. Lundbeck A/S	The use of enantiomeric pure escitalopram
AR034612A1 (es)	2001-06-25	2004-03-03	Lundbeck & Co As H	Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
MXPA05005772A (es) *	2002-12-23	2005-08-16	Lundbeck & Co As H	Bromhidrato de escitalopram y un metodo para su preparacion.
US20050174782A1 (en) *	2003-03-25	2005-08-11	Chapman Leonard T.	Flashlight

2003
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Application Discontinuation
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en active IP Right Grant
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
2006
- 2006-07-18 HK HK06108012A patent/HK1087708A1/xx not_active IP Right Cessation
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN1726202A (zh)	2006-01-25
EP1578738B1 (en)	2008-03-12
DK1578738T3 (da)	2008-06-30
UY28148A1 (es)	2004-09-30
CA2511142A1 (en)	2004-07-08
MY135468A (en)	2008-04-30
UA80170C2 (en)	2007-08-27
ES2298595T3 (es)	2008-05-16
AU2003287919A1 (en)	2004-07-14
JP2006514952A (ja)	2006-05-18
DE60319739T2 (de)	2008-07-17
MXPA05005772A (es)	2005-08-16
MEP5808A (xx)	2010-02-10
EA200501046A1 (ru)	2005-12-29
AR042652A1 (es)	2005-06-29
IS7848A (is)	2005-05-17
BR0317623A (pt)	2005-11-29
JP2011037893A (ja)	2011-02-24
RS51092B (sr)	2010-10-31
PE20040924A1 (es)	2004-12-11
NO20053595L (no)	2005-09-05
IS2654B (is)	2010-08-15
AU2003287919B2 (en)	2009-11-12
PL378275A1 (pl)	2006-03-20
WO2004056791A1 (en)	2004-07-08
EP1578738A1 (en)	2005-09-28
EG24729A (en)	2010-06-21
TW200501943A (en)	2005-01-16
KR20050086933A (ko)	2005-08-30
ATE388947T1 (de)	2008-03-15
HK1087708A1 (en)	2006-10-20
IL169125A0 (en)	2009-02-11
NZ540281A (en)	2008-07-31
CN100349885C (zh)	2007-11-21
DE60319739D1 (de)	2008-04-24
US20040167209A1 (en)	2004-08-26
CY1107451T1 (el)	2012-12-19
RS20050487A (en)	2007-06-04
EA013116B1 (ru)	2010-02-26
JP4658613B2 (ja)	2011-03-23
PT1578738E (pt)	2008-04-11

Publication	Publication Date	Title
ZA200504109B (en)	2006-08-30	Escitalopram hydrobromide and a method for the preparation thereof
AU2001100399A4 (en)	2001-11-01	Process for the preparation of pure citalopram
EP1181713B1 (en)	2004-09-29	Method for the preparation of pure citalopram
BR9917368B1 (pt)	2010-02-09	mÉtodo para preparaÇço de citalopram.
TW201144291A (en)	2011-12-16	New process for the preparation of dronedarone
NZ521200A (en)	2004-03-26	Method for the preparation of citalopram
US20100204493A1 (en)	2010-08-12	Process for the Preparation of Escitalopram
JPH08510477A (ja)	1996-11-05	新規なｎ−ベンゾイルメチル−ピペリジン類
US20050137255A1 (en)	2005-06-23	Crystalline escitalopram hydrobromide and methods for preparing the same
EP1485367B1 (en)	2007-08-01	Purified citalopram salts
WO2003042202A1 (en)	2003-05-22	Isobenzofuran derivatives
KR20140020981A (ko)	2014-02-19	메실화에 의한 드로네다론의 제조방법